Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and/or Camrelizumab vs Chemotherapy in PD-1 Refractory NPC
NCT05549466Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib and camrelizumab in nasopharyngeal carcinoma (NPC) (4 arms), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05549466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549466.